γ-Hydroxybutyric acid and its relevance in neurology

Neurology

Volumn 72, Issue 3, 2009, Pages 282-286

  Benarroch, Eduardo E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 HYDROXYBUTYRIC ACID; BACLOFEN; ETHOSUXIMIDE; GLUTAMIC ACID; OXYBATE SODIUM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUCCINATE SEMIALDEHYDE DEHYDROGENASE; VALPROIC ACID; VIGABATRIN; VOLTAGE GATED CALCIUM CHANNEL; 4-HYDROXYBUTYRIC ACID; ALDH5A1 PROTEIN, HUMAN; HYDROXYBUTYRIC ACID; NEUROPROTECTIVE AGENT;

ANTEROGRADE AMNESIA; AUTOSOMAL RECESSIVE DISORDER; CATAPLEXY; DEATH; DELTA RHYTHM; DROWSINESS; DRUG DEPENDENCE; DRUG MECHANISM; HUMAN; MEMORY DISORDER; NARCOLEPSY; NERVE EXCITABILITY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REM SLEEP; RESPIRATION DEPRESSION; SEIZURE; SHORT SURVEY; SIDE EFFECT; SLOW WAVE SLEEP; SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; VENTRAL TEGMENTUM; ADDICTION; ALCOHOLISM; ARTICLE; BRAIN; METABOLISM; NEUROLOGIC DISEASE; NEUROLOGY;

ALCOHOLISM; BRAIN; HUMANS; HYDROXYBUTYRATES; NARCOLEPSY; NERVOUS SYSTEM DISEASES; NEUROLOGY; NEUROPROTECTIVE AGENTS; SUBSTANCE-RELATED DISORDERS; SUCCINATE-SEMIALDEHYDE DEHYDROGENASE;

EID: 59649101905     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000341945.28830.88     Document Type: Article

References (22)

1. Maitre M. The gamma-hydroxybutyrate signaling system in brain: organization and functional implications. Prog Neurobiol 1997;51:337-361.
2. Wong CG, Gibson KM, Snead OC, 3rd. From the street to the brain: neurobiology ofthe recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 2004;25:29-34.
3. Crunelli V, Emri Z, Leresche N. Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol 2006;6:44-52.
4. Drasbek KR, Christensen J, Jensen K. Gamma-hydroxy- butyrate-a drug of abuse. Acta Neurol Scand 2006;114: 145-156.
5. Gupta M, Hogema BM, Grompe M, et al. Murine succi- nate semialdehyde dehydrogenase deficiency. Ann Neurol 2003;54 Suppl 6:S81-90.
6. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hyper- somnias of central origin. Sleep 2007;30:1705-1711.
7. Robinson DM, Keating GM. Sodium oxybate: a review of its use in the management of narcolepsy. CNS Drugs 2007;21:337-354.
8. Knerr I, Pearl PL, Bottiglieri T, Snead OC, Jakobs C, Gibson KM. Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma- hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology. J Inherit Metab Dis 2007;30:279-294.
9. Andriamampandry C, Taleb O, Kemmel V, Humbert JP, Aunis D, Maitre M. Cloning and functional characterization of a gamma-hydroxybutyrate receptor identified in the human brain. Faseb J 2007;21:885-895.
10. Castelli MP, Mocci I, Langlois X, et al. Quantitative auto- radiographic distribution of gamma-hydroxybutyric acid binding sites in human and monkey brain. Brain Res Mol Brain Res 2000;78:91-99.
11. Wu Y, Ali S, Ahmadian G, et al. Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. Neuropharmacology 2004;47:1146-1156.
12. Castelli MP, Pibiri F, Carboni G, Piras AP. A review of pharmacology of NCS-382, a putative antagonist of gamma-hydroxybutyric acid (GHB) receptor. CNS Drug Rev 2004;10:243-260.
13. Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. J Clin Invest 1997;100:745-753.
14. Llinas RR, Steriade M. Bursting of thalamic neurons and states of vigilance. J Neurophysiol 2006;95:3297-3308.
15. Gervasi N, Monnier Z, Vincent P, et al. Pathway-specific action of gamma-hydroxybutyric acid in sensory thalamus and its relevance to absence seizures. J Neurosci 2003;23: 11469-11478.
16. Pistis M, Muntoni AL, Pillolla G, et al. Gamma- hydroxybutyric acid (GHB) and the mesoaccumbens reward circuit: evidence for GABA(B) receptor-mediated effects. Neuroscience 2005;131:465-474.
17. Cruz HG, Ivanova T, Lunn ML, Stoffel M, Slesinger PA, Luscher C. Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat Neurosci 2004;7:153-159.
18. Mamelak M. Alzheimer' s disease, oxidative stress and gammahydroxybutyrate. Neurobiol Aging 2007;28:1340-1360.
19. Jansen EE, Verhoeven NM, Jakobs C, et al. Increased gua- nidino species in murine and human succinate semialde- hyde dehydrogenase (SSADH) deficiency. Biochim Biophys Acta 2006;1762:494-498.
20. Nava F, Premi S, Manzato E, Campagnola W, Lucchini A, Gessa GL. Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam. Am J Drug Alcohol Abuse 2007;33:379-392.
21. Havaligi N, Matadeen-Ali C, Khurana DS, Marks H, Kothare SV. Treatment of drop attacks in Coffin-Lowry syndrome with the use of sodium oxybate. Pediatr Neurol 2007;37:373-374.
22. Berner JE. A case of sodium oxybate treatment of tardive dyskinesia and bipolar disorder. J Clin Psychiatry 2008;69: 862.